Exonhit Receives "Innovative Company" Accreditation from the French State Innovation Agency OSEO

PARIS--(Business Wire)--
Regulatory News:

ExonHit Therapeutics (Paris:ALEHT) (Alternext: ALEHT) today announced that it
has obtained the "Innovative Company" accreditation from OSEO (the French state
innovation agency), in recognition of the company's cutting-edge innovations in
its target sectors. The accreditation means that French innovation-focused
mutual funds (FCPI) can now make tax-efficient equity investments in ExonHit
Therapeutics for renewable 3-year periods.

"We are delighted to have received this OSEO accreditation, which emphasizes our
particularly innovative strategy in genomic profiling that we apply both in
therapeutics and in diagnostics. We are continuing our investments and research
efforts with a view to offering personalized medical solutions in Alzheimer's
disease and cancer - both of which are major public health issues", commented
Loïc Maurel MD, President of the Management Board at ExonHit Therapeutics.

This new milestone forms part of ExonHit's unrelenting commitment to innovation
in the fields of neurodegenerative diseases and oncology. It follows on from
last December's launch of AclarusDx the company's first research-use-only
molecular test for Alzheimer's disease.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast-emerging healthcare player
active in both therapeutics and diagnostics. The company is applying its
proprietary technology, based on the analysis of alternative RNA splicing, to
develop innovative molecular diagnostic tests and therapeutics for
neurodegenerative and cancer indications. ExonHit has a balanced investment
strategy with in-house development programs and strategic collaborations, in
particular with bioMérieux and Allergan).

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg,
Maryland. The company is listed on Alternext of NYSE Euronext Paris. For more
information, please visit http://www.exonhit.com.

Disclaimer

This press release contains elements that are not historical facts including,
without limitation, certain statements on future expectations and other
forward-looking statements. Such statements are based on management`s current
views and assumptions and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates,
directors, officers, advisors and employees have not verified the accuracy of,
and make no representations or warranties in relation to, statistical data or
predictions contained in this press release that were taken or derived from
third party sources or industry publications, and such statistical data and
predictions are used in this press release for information purposes only.

Lastly, this press release may be drafted in the French and English languages.
In an event of differences between the texts, the French language version shall
prevail.

ExonHit Therapeutics
Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com
or
Alize RP
Caroline Carmagnol
+ 33 6 64 18 99 59
caroline@alizerp.com

Copyright Business Wire 2010